Glenmark Pharmaceuticals Ltd (GLENMARK) — shareholding pattern, promoter holding, financials and share price
About Glenmark Pharmaceuticals Ltd (GLENMARK)
Glenmark Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GLENMARK and on the BSE under scrip code 532296. Its ISIN is INE935A01035.
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. [1]
Glenmark Pharmaceuticals Limited is actively involved in the development, manufacture, and marketing of pharmaceutical products, focusing on formulations and active pharmaceutical ingredients. Its core areas include oncology, respiratory, and dermatology, serving major global markets.
The company’s Q3 FY26 results emphasize a consolidated revenue surge of 15.1% YoY, underscoring its robust execution across international markets, particularly India, which saw 22.1% growth buoyed by strong performance in dermatology and respiratory therapies.
Listed peers in Pharmaceuticals: Laurus Labs Ltd, Biocon Ltd, Alkem Laboratories Ltd, Abbott India Ltd, Ipca Laboratories Ltd, Ajanta Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹2,276.1 a share on 10 Jul 2026, Glenmark Pharmaceuticals Ltd (GLENMARK) was valued at a price-to-earnings ratio of 47.16x against an industry P/E of 36.41x and a price-to-book of 7.26x on a book value of ₹313.59 per share as of Mar 2025. Solomo computes return on equity of 15.39% and return on capital employed of 19.37% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 47.16x
- Industry P/E
- 36.41x
- P/B
- 7.26x
- EPS (TTM)
- ₹48.26
- Book value / share
- ₹313.59
- ROE
- 15.39%
- ROCE
- 19.37%
- ROA
- 8.49%
- Debt / equity
- 0.28x
- Dividend yield
- 0.22%
- EBITDA margin
- 16.56%
- 52-week range
- ₹1,794 – ₹2,471.05
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Glenmark Pharmaceuticals Ltd (GLENMARK) reported revenue of ₹16,983 crore, net profit of ₹1,362 crore and earnings per share of ₹48.26. That compares with revenue of ₹13,322 crore and net profit of ₹1,047 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3,771 crore and net profit ₹301 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 |
| Net profit (₹ cr) | 994 | 377 | -1,434 | 1,047 | 1,362 |
| EPS (₹) | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.51% | 6.57% | 4.26% | 12.77% |
| Profit growth | 0.91% | 3.52% | -6.93% | -173.05% |
| Stock price CAGR | 11% | 27% | 48% | 4% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.65% of Glenmark Pharmaceuticals Ltd (GLENMARK) (unchanged from the previous quarter), foreign institutional investors (FII) hold 20.89% and domestic institutional investors (DII) hold 18.6%. Market capitalisation was ₹64,232 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HDFC MUTUAL FUND - HDFC MID-CAP FUND 6.22%, GOVERNMENT PENSION FUND GLOBAL 3.89%, AMANSA HOLDINGS PRIVATE LIMITED 2.22%, INVESCO INDIA CONTRA FUND 2.2%, BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND 1.28%, UTI MULTI CAP FUND 1.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.65% | - | 20.89% | 18.6% | 53.35% |
| Mar 2026 | 46.65% | - | 20.34% | 19.29% | 53.35% |
| Dec 2025 | 46.65% | - | 19.2% | 20.09% | 53.35% |
| Sep 2025 | 46.65% | - | 20.73% | 18.61% | 53.35% |
| Jun 2025 | 46.65% | - | 20.62% | 17.64% | 53.35% |
| Mar 2025 | 46.65% | - | 23.16% | 14.6% | 53.35% |
| Dec 2024 | 46.65% | - | 23.51% | 13.85% | 53.35% |
| Sep 2024 | 46.65% | - | 23.05% | 13.21% | 53.35% |